fashion -WSS

fashion

author：comprehensive 2025-09-27 21:54:28 - browse：3

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Surge in Apellis stock fueled by confidence in safety of its eye drug

leisure time

WSS

Illinois Supreme Court finds assault weapons ban constitutional

YouTube cracks down on misinformation on cancer treatment

Australia’s approach to dialysis celebrates life

Treatments for cramps don't cut it. Why aren't there better options?

How Long Island became the ‘eugenics capital of the world’

Departing Stanford president retracts two papers

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Novavax promises a turnaround & Lilly roils the obesity market

Novo Nordisk touts Wegovy study, but still struggling with supply

How one medical school became remarkably diverse

YouTube cracks down on misinformation on cancer treatment

Walensky prepares to leave CDC — and Congress — behind

Be careful with at

Medicare details structure of new drug price negotiation program

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Jerome Adams on the need for new antivirals for Covid

Study finds new variant for Parkinson’s in African populations

Wikipedia

Idaho college killings prosecutors challenge defense's grand jury claims

What to know about the judge who will handle the Trump case

YouTube cracks down on misinformation on cancer treatment

Apellis safety probe of eye disease drug centers on injection needle

YouTube cracks down on misinformation on cancer treatment

Hospitals are dialing back on venture capital investing

hotspot

entertainment

leisure time

entertainment